Table 1.
Demographic and Basic Clinical Data for Patients With Tick-borne Encephalitis Vaccine Failure in Stockholm County, Sweden, 2006–2015
| Characteristic | n (%) (n = 53) | Median (Range) |
|---|---|---|
| Age (y) | … | 62 (6–83) |
| Male | 34 (64) | … |
| Number of vaccine doses | … | 3 (2–9) |
| Number of months since last dose | … | 23 (<1–50)a |
| Comorbidity | 27 (51) | … |
| Neurological disease | 5 (9) | … |
| Psychiatric disease | 2 (4) | … |
| Cardiovascular disease | 12 (23) | … |
| Hematological malignancy | 2 (4) | … |
| Other malignanciesb,c | 3 (6) | … |
| Inflammatory diseasec | 10 (19) | … |
| Diabetes mellitus | 4 (8) | … |
| Immunosuppressive therapy | 8 (15) | … |
| Prednisolone equivalentsd | 2 (4) | … |
| Methotrexatee | 5 (9) | … |
| Other immunosuppressive drugsf | 4 (8) | … |
aFour patients became ill less than 1 month after their last dose (dose 3 or 5).
bProstate or breast cancer.
cOne patient with both rheumatic disease and breast cancer.
dDose 2.5 mg or 5 mg/day.
eDose 10–20 mg/week.
fAzatioprine, mesalazine, etanercept, hydroxychloroquine.